If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

Our Mission

The NOVEL observational longiTudinal studY (NOVELTY) is a global, prospective, 3-year observational study of patients with a diagnosis or suspected diagnosis of asthma and/or COPD. NOVELTY aims to describe patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, providing real-world evidence to advance the development of precision medicine to deliver the right treatment to the right patient at the right time. The NOVELTY study is sponsored by AstraZeneca.

Information for the general public

NOVELTY study animation

Watch our short animation to learn more about the NOVELTY study.

NOVELTY at ERS 2020

Six NOVELTY ePosters were presented at the virtual ERS Congress 2020, and the related abstracts have now been published online.

Observational studies review published

We are pleased to announce that ‘Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design’ has been published.

Publications & presentations

Read summaries of publications and presentations relating to the NOVELTY study and access useful NOVELTY resources.

For investigators

Access news updates, research requests, resources and frequently asked questions relating to the NOVELTY study.

For AstraZeneca Medical employees

Access news updates, research requests, resources and frequently asked questions relating to the NOVELTY study.

19 PARTICIPATING COUNTRIES^a

~12,000 ENROLLED PATIENTS^a

80% OF PATIENTS HAVE SPIROMETRY DATA^b

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study